



## Theratechnologies Closes \$29,750,000 Financing

*Not for distribution to U.S. news wire services or dissemination in the United States.*

**Montreal, Canada, February 13, 2008** - Theratechnologies Inc. (TSX: TH) today announced that it has successfully completed its recently announced public offering of 3,500,000 common shares at a price of \$8.50 per share for gross proceeds of \$29,750,000. The offering was made through a syndicate of underwriters led by BMO Capital Markets, including Canaccord Capital, National Bank Financial, Desjardins Securities and Jennings Capital. The Company has also granted to the underwriters an over-allotment option to purchase an additional 350,000 common shares at the same price (\$2,975,000), exercisable by the underwriters for a period of 30 days from closing.

The net proceeds of the offering will be used by Theratechnologies primarily to finance the continuing development of tesamorelin, to finance part of its commercialization efforts, and for working capital purposes.

The securities offered have not been registered under the *U.S. Securities Act of 1933*, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy in any jurisdiction nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

### **About Theratechnologies**

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, now in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

### **Information:**

Luc Tanguay  
Senior Executive Vice President and  
Chief Financial Officer  
Phone: 514-336-4804, ext. 204  
[ltanguay@theratech.com](mailto:ltanguay@theratech.com)

Andrea Gilpin  
Executive Director, IR & Communications  
Phone: 514-336-4804, ext. 205  
[communications@theratech.com](mailto:communications@theratech.com)

Theratechnologies Inc.

2310 Alfred-Nobel Blvd., Montréal, Québec, Canada H4S 2A4

Phone: (514) 336-7800 • Fax: (514) 336-7242 • [www.theratech.com](http://www.theratech.com) • [thera@theratech.com](mailto:thera@theratech.com)